Sorivudine

Drug Profile

Sorivudine

Alternative Names: Bravavir®; Brovavir; BV-ara-U; BVAU; SQ 32756; Usevir; YN 72

Latest Information Update: 29 Oct 1997

Price : $50

At a glance

  • Originator Azwell; Yamasa Corporation
  • Developer Azwell; Bristol-Myers Squibb; Yamasa Corporation
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Market Withdrawal Herpes zoster

Most Recent Events

  • 29 Oct 1997 Discontinued-III for Herpes zoster in Switzerland (PO)
  • 29 Oct 1997 Discontinued-III for Herpes zoster in United Kingdom (PO)
  • 29 Oct 1997 Discontinued-III for Herpes zoster in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top